Compare equities side by side
Stocks breaking to new annual highs
S&P 500 oversold value screener
Relative strength momentum leaders
Upcoming earnings dates & reports
Filter and sort all 500 stocks
Continuous multi-factor scoring & catalyst forensics
Today's biggest gainers and losers
Precision BioSciences is a clinical-stage gene editing company developing in vivo and ex vivo therapies using its proprietary ARCUS genome editing platform. The company focuses on allogeneic CAR-T cell therapies for hematologic malignancies and solid tumors, plus in vivo gene editing programs for genetic diseases. With minimal revenue ($0.1B TTM) and cash burn of ~$0.1B annually, the stock trades on clinical trial milestones, partnership announcements, and runway visibility.
Precision generates revenue through upfront payments, research funding, and milestone payments from pharma partnerships licensing its ARCUS platform. The company's competitive advantage lies in its proprietary base editor technology that enables precise single-base DNA changes without double-strand breaks, potentially offering safer gene editing versus CRISPR-Cas9. Long-term value depends on successfully advancing allogeneic CAR-T candidates (PBCAR0191, PBCAR269A) through clinical trials and achieving regulatory approval. The 100% gross margin reflects the service/IP licensing nature of current revenue with minimal COGS.
Clinical trial data readouts for lead CAR-T programs (PBCAR0191 for NHL, PBCAR269A for multiple myeloma) - safety, efficacy, durability signals
Partnership announcements or expansions with major pharma companies providing non-dilutive funding and validation
Cash runway updates and financing events (equity raises, debt facilities) given negative FCF of $0.1B annually
Regulatory milestones including IND clearances for new programs or FDA interactions on pathway to approval
Competitive developments in allogeneic CAR-T space from Allogene, Caribou Biosciences, CRISPR Therapeutics
Allogeneic CAR-T field faces fundamental challenges including graft-versus-host disease, limited persistence, and tumor rejection - multiple competitors have experienced clinical setbacks
Regulatory pathway uncertainty for gene-edited cell therapies with FDA requiring extensive long-term safety monitoring and potential manufacturing complexity
Reimbursement pressure on high-cost cell therapies (typically $400K-500K per treatment) as payers scrutinize value and health systems face budget constraints
Intense competition from better-capitalized gene editing players (CRISPR Therapeutics $2B+ market cap, Editas $300M+) and established autologous CAR-T leaders (Gilead/Kite, BMS/Juno)
Risk that ARCUS platform fails to demonstrate meaningful differentiation versus CRISPR-Cas9 or base editing approaches from competitors, limiting partnership value
Potential for breakthrough competing technologies (in vivo CAR-T, off-the-shelf NK cells) to obsolete allogeneic CAR-T approach before commercialization
Critical cash runway risk - with $0.1B annual burn and $0.1B market cap, company likely needs financing within 12-18 months absent major partnership influx
1.75x debt/equity indicates meaningful leverage for pre-revenue company; debt covenants may restrict operational flexibility or force dilutive equity raise
Negative ROE of -213% and ROA of -90% reflect severe cash consumption; equity raises at current depressed valuation ($0.1B market cap) would be highly dilutive to existing shareholders
low - Pre-revenue biotech with minimal direct GDP linkage. Clinical trial timelines and regulatory processes largely insulated from economic cycles. However, severe recessions can impact: (1) ability to raise capital at favorable terms, (2) pharma partners' willingness to fund collaborations, (3) healthcare system capacity to enroll trials.
Rising rates negatively impact valuation through higher discount rates applied to distant future cash flows (therapies unlikely to reach market before 2028-2030). Higher rates also increase cost of debt financing and make equity raises more dilutive. The 3.45x current ratio provides liquidity buffer, but 1.75x debt/equity indicates meaningful interest expense sensitivity. Additionally, rising rates can reduce biotech M&A activity and partnership deal flow.
Moderate - Company depends on access to capital markets for survival given negative operating cash flow. Tightening credit conditions reduce availability of venture debt and make equity raises more challenging/dilutive. High-yield credit spreads serve as proxy for risk appetite in speculative biotech financing. However, strategic pharma partnerships provide some insulation from pure credit market dynamics.
growth - Attracts speculative biotech investors and venture-stage funds willing to accept binary clinical risk for potential 5-10x returns if therapies succeed. The -22% YTD return, negative cash flow, and pre-revenue status make this pure risk capital. Not suitable for value or income investors. Requires high risk tolerance and portfolio diversification given single-digit probability of ultimate commercial success typical for clinical-stage assets.
high - Small-cap biotech ($0.1B market cap) with binary clinical catalysts creates extreme volatility. Stock can move 30-50% on single trial data points. The -22% 3-month and -15% 6-month returns demonstrate downside volatility, while low liquidity amplifies price swings. Estimated beta likely 1.5-2.0x versus biotech indices.
